Document:

Exhibit 10.127

 

CONSULTING SERVICES CONTRACT

 

Agreement entered into this day of 17 July, 2013 between CHRYSALIS
PHARMA PARTNERS, LLC (hereinafter “Consultant”) with a principal place of business at 385 Route 24, Suite 1G, Chester,
N.J. 07930 and VG Life Sciences, Inc. (hereinafter “Company”) with a principal place of business at 121 Gray Avenue,
Santa Barbara, CA 93101.

 

WHEREAS, Consultant is in the business of providing consulting
services in the drug development field with specific focus on strategic considerations, preclinical aspects and toxicology and
drug metabolism.

 

WHEREAS, Company is developing therapies for unmet medical
needs.

 

WHEREAS, Company desires to have Consultant provide such
services upon the terms and conditions set forth in this Agreement and Consultant desires to provide such services to Company as
described above, and as more fully set forth in this Agreement.

 

WHEREAS, Consultant and Company warranty and represent
that each has the authority to enter into this Contract and to perform all obligations hereunder.

 

NOW, THEREFORE, in consideration of the mutual covenants
and promises set forth herein, the parties agree as follows:

 

1.       Term of Agreement. This agreement shall
commence on 25SEP2013 and shall continue in full force and effect unless terminated upon written notice of intent to terminate
by either party or unless otherwise terminated pursuant to this agreement. Consultant and Company shall have the right to terminate
this agreement upon 20 days written notice.

 

2.       Duties and Obligations. 

 

(a)Consultant shall perform the duties and have the obligations
pursuant to this agreement as more particularly set forth on Exhibit A attached hereto:

 

(b)Company shall have the following obligations pursuant
to this agreement: Provide all information necessary for Consultant to perform its duties and any additional duties described in
detail in Exhibit A.

 

3.       Independent Contractor. Consultant is an
independent contractor and not an employee, servant, agent or joint venturer of or with Company. All persons that perform any
of the duties or obligations of Consultant pursuant to this agreement are employees, servants, independent contractors or agents
of Consultant and not Company. Consultant will indemnify and hold harmless Company from and against any and all claims, damages,
losses or liability which shall arise from or are connected to the taxes of Consultant, its employees, servants, independent contractors
or agents. Company acknowledges that Consultant may perform similar services for other companies. Consultant is not eligible for,
or entitled to, and shall not participate in, any of the health, pension or fringe benefit plans of Company, if any exist. Participation
in these plans is limited to employees of Company.

 

    	1

    	 

    

 

 

 

 

4.       Licensure.
Consultant, and all persons to perform services pursuant to this agreement, shall be required to maintain and provide Company
with evidence of proper licensure and appropriate certification or accreditation, if required by any governing body, or set forth
in the duties herein, during the term of this agreement.

 

5.       Billing.
Company shall pay Consultant pursuant to Schedule B attached hereto. In addition, Consultant shall be reimbursed for reasonable
and customary travel expenses, if any, incurred by Consultant in the performance of such services for Company upon receipt of
all supporting documentation. Company shall not be responsible or liable for any course, expenses or charges for services performed
by Consultant unless prior written confirmation has been provided by Company.

 

6.       Confidential
Information.

 

(a)       Access
to books and records: Each party, its agents, employees and any independent contractors hired to perform services
pursuant to this Agreement, may receive and have access to information, technical data, records, documents of the other party,
of any kind whatsoever, including, but not limited to, technical data, analyses, studies, client information and lists, fee structures,
financial information, research and development, future plans and other personal or professional information, and receive information
concerning the other during conversations with staff or agents of the other party, all information so obtained being Confidential
Information and/or Trade Secrets to the other party, and subject to the Confidentiality Agreement. The availability of the books
and records shall be subject to any and all applicable Health and Human Services rules and regulations and other applicable laws
or regulations. If either party enters into any agreement with a subcontractor to provide services to the other party, the subcontracting
party shall ensure that the above described provision regarding access to books, documents and records is part of any such agreement.

 

(b)       Media:
Consultant shall not submit for publication any paper containing any Confidential Information or data without the written permission
of Company. Consultant may not utilize any reference to Company in any publicity, press release or advertising, including any
reference to this Contract for Services or the Confidentiality Agreement, without the written permission of Company.

 

(c)      Intellectual Property:
All concepts, inventions, ideas, patent rights, data, trademarks, copyrights and/or other intellectual property rights which arise
out of any work related to this Contract, or work product, are the exclusive property of Company and all ownership rights are
vested in Company. Consultant agrees that it will sign all necessary documents or take such other actions as Company may reasonably
request in order to perfect any and all such rights.

 

    	2

    	 

    

 

7.       No Assignment. Consultant shall have no
authority to assign their obligations pursuant to this Contract without the prior written consent of Company. Company shall be
entitled to assign their obligations to a subsidiary, affiliate or related Consultant.

 

8.       Arbitration

 

	(a)		If any dispute arises between the parties hereto with respect to this Agreement and/or
performance under the Agreement, the dispute shall be submitted to binding arbitration before the American Arbitration Association
in Morris County, N.J.

 

	(b)		Each party shall be responsible for fifty (50%) of the arbitration cost.

 

	(c)		This Agreement shall be interpreted, enforced and governed by the substantive laws
of the State of New Jersey and the decision of the arbitrator shall be enforceable in the New Jersey Courts.

 

	(d)		The breaching party shall pay to the non-breaching party all of the non-breaching
party’s costs and expenses, including attorney fees, incurred by such party in enforcing the terms of this Agreement.

 

9.       Supervision. Consultant shall not be subject
to the provisions of any personnel handbook or the rules and regulations applicable to employees of Company since Consultant shall
fulfill his responsibilities independent of, and without supervisory control, by Company.

 

10.     Compliance. In the performance of the
project, each party agrees to comply with all applicable laws, rules and regulations as well as any applicable ethics rules. Each
party further agrees to make all required disclosures and obtain all approvals concerning this Agreement that are required by
law, rule or regulation, including any required notification to a relevant ethics committee or government agency. If Consultant
is an employee with any other person or entity, such employer must also sign this Agreement.

 

11.      Indemnification and Liability:

 

	a.		Liability. In no event shall Consultant be liable to Company whether a claim be in
tort, contract or otherwise (a) for any amount in excess of the total professional fees paid by Company to Consultant under this
Agreement, or (b) for any consequential, indirect or similar damages related to services provided under this agreement, except
to the extent finally determined to have resulted from willful misconduct or fraud by Consultant relating to such services.

	b.		Company agrees to indemnify and hold harmless Consultant from any and all third party
claims, liabilities, costs and expenses relating to services provided under this Agreement, except to the extent finally determined
to have resulted from willful misconduct or fraudulent behavior by Consultant relating to such services.

	c.		Consultant will not use the business relationship with Company to advertise its consulting
services nor otherwise promote business. Conditions set forth in this Agreement shall be disclosed publicly only when required
by appropriate legal authority.

 

    	 

    	 

    

12.       Termination. Immediately upon the receipt
of written notice that this Agreement shall be terminated, Consultant shall immediately cease work, deliver to Company all work
performed to date, and return all Confidential Information as described herein and in the Confidentiality Agreement. Upon such
termination, Company shall be obligated to pay Consultant any monies due and owing up through the termination date for services
actually performed and all reasonable expenses actually incurred.

 

13.       Headings.The
headings have been inserted for convenience only and are not to be

considered when construing the provisions of this Agreement.

 

14.       Modification.
No alteration or modification to any of the provisions of this Agreement shall be valid unless in writing and signed by both
parties.

 

15.       Miscellaneous

 

	(a)		Company retains administrative and professional responsibility for the services performed
herein solely to comply with the requirements of Medicare and Medicaid programs. Consultant specifically agrees to be responsible
for its own acts and omission of any person who performs any duties or obligations of Consultant.

	(b)		Any notice required under this agreement shall be by certified mail, return receipt
requested, or by next day delivery service, addressed as following:

 

Consultant: James MacDonald (address as set forth above); Company:
John Tynan (address as set forth above) and shall be deemed received three days after days after mailing or one actually received,
whichever is earlier.

 

	(a)		The parties agree that they shall not discriminate on account of race, sex, color,
religion, national origin or handicap or other characteristic protected by law.

	(b)		Consultant agrees to keep confidential all medical and nursing records of, and all
other information about, each person.

	(c)		There are no third party beneficiaries of or to this Agreement.

 

17.Complete agreement

 

This Agreement is the sole and entire agreement between the parties relating to the subject matter hereof,
and supersedes all prior understanding, agreements and documentation on this matter. Only an instrument executed in writing by
both parties may amend this Agreement. If any provisions of this Agreement are deemed unenforceable, that provision shall not invalidate
the remaining provisions contained in this Agreement, and they shall continue in full force and effect.

 

    	3

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have executed
this Agreement as of the date set forth above.

 

	/s/ James MacDonald	/s/ illigible
	CHRYSALIS PHARMA PARTNERS, LLC	VG Life Sciences, Inc.
	By: JAMES MACDONALD, PRESIDENT	By:John P. Tynan
	Date: 23SEP2013	Date: 9/23/2013

 

 

    	4

    	 

    

 

 

EXHIBIT A 

SCHEDULE OF DUTIES AND OBLIGATIONS

 

Consultant: James MacDonald will review material sent by Company
with a specific focus on the appropriateness of the proposed preclinical toxicology program to support the desired indication.
This review may expand to a review of materials necessary for Consultant to provide advice to the Company on the most appropriate
indication to pursue to enable rapid transit into clinical trials. To facilitate this expanded conversation, Consultant will contract
with Dr. Catherine Strader of Artemis Pharma Partners, LLC to take advantage of her expertise in bringing new molecules forward
from discovery. Under this scenario, Dr. Strader would be required to sign a CDA with Company in addition to Consultant. The specific
deliverable of this engagement is a recommendation to the Company on next steps the Company may wish to consider with respect to
its preclinical first-in-human enabling program. Depending on the outcome of these initial discussions, Consultant may be asked
to perform additional duties with regard to supporting the development program at the direction of Company. If this occurs, this
agreement will be amended to reflect the change in scope.

 

EXHIBIT B 

COMPENSATION

 

Company will pay Consultant for the services specified above
at a rate of USD 450/hr ($ 3600/day). Payment will be expected 30 days after Consultant submits an invoice to Company detailing
the work performed.

 

Consultant will provide an initial review of the preclinical toxicology program with a not to exceed amount
of $15,000 unless the Company agrees to an increase. Consultant will then outline a budget for its services beyond this initial
review for the Company’s approval.Exhibit 10.128

 

CONSULTING AGREEMENT

 

THIS
CONSULTING AGREEMENT (the "Agreement") is made and entered into by and between VIRAL GENETICS, INC., a Delaware corporation
(the "Company"), and Dr. Eric S. Rosenberg, an individual residing in the city of Milton, MA ("Consultant")
effective this 1st day of July, 2006.

 

(the "Parties")

 

WHEREAS the Company is
an early-stage business engaged in the development of certain technologies, investigational drugs, pharmaceutical products, and
medical knowledge ("Technology"); and

 

WHEREAS Consultant has
experience, knowledge, contacts, and skills which are beneficial to the development of the Company and its areas of focus; and

 

WHEREAS the Company wishes
to engage Consultant and to define the nature of the relationship, to protect certain confidential information owned or possessed
by the Company, and to establish certain other representations, warranties and covenants.

 

NOW THEREFORE, for good
and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows.

 

1)Non-Exclusive Engagement of Consultant;
Term. The Company hereby engages Consultant as its nonexclusive provider of the consulting services described in this Agreement,
for a term (the "Term"), which will commence on the date of this Agreement and end June 30, 2008.

 

2)Consultant Services. On the terms
and conditions set forth in this Agreement, Consultant will provide the following services to the Company as directed by the Company
(the "Services"):

 

	a)		Consultant agrees to appointment as Chairman of the Scientific and Medical Advisory
Board of the Company ("SAB"). Consultant has read, understood, and accepted the SAB Charter, attached hereto as Exhibit
A;

	b)		Consultant will advise and assist the Company with the worldwide development, evaluation,
analysis, testing, research, and study of its Technology;

	c)		Consultant shall advise and assist the Company with respect to the authorship, presentation
and publication of reports, results, analyses, studies and other scientific and medical activities of the Company, in recognized
peer-reviewed literature or industry conferences, as mutually agreed to. To this end, Consultant shall, with reasonable notice,
be available for personal appearances on behalf of the Company from time to time at medical and scientific conferences where the
fact of and nature of such an appearance would not reasonably affect the perception of Consultant's independence and scientific
objectivity; review, edit and provide comment on any manuscripts or abstracts relating to the Technology, whether authored by
the Company or not;

	d)		Consultant will advise and assist the Company on other medical issues with respect
to the Company's products and drug candidates;

	e)		Consultant will advise and assist the Company on increasing the depth, effectiveness,
and visibility of the SAB. To this end, Consultant shall identify and recruit a team of four to eight immunologists, virologists,
statisticians, clinical trials experts, and/or such other experts as Consultant deems necessary to effectively carry out the duties
of the SAB. Such candidates shall be subject to the approval of the Company, taking into consideration such matters as potential
conflicts of interest;

 

    	1

    	 

    

 

 

	f)		Consultant shall from time to time and as requested present the conclusions and recommendations
of the SAB to the board of directors of the Company and be available to respond to questions from board members. In connection
with this, Consultant may be asked to attend board meetings, whether by teleconference or in person, the latter at the Company's
expense, solely in the capacity as a non-voting observer; and

	g)		Consultant will assist and advise the Company in other areas in which Consultant has
expertise as reasonably requested from time to time by the Company.

 

Services shall not (i) involve any use of the
facilities, space, materials or other resources of The General Hospital Corporation d/b/a Massachusetts General Hospital ("Hospital"),
including resources provided in-kind by outside sources (provided that use alone by the Consultant of the Consultant's office space
and word processor shall not be considered a prohibited use of such Hospital resources), or (ii) use direct or indirect financial
support from Hospital, including funding from any outside source awarded to or administered by Hospital. In the event that the
Services overlap with a field in which the Consultant is performing research at Hospital sponsored by a third party for-profit
entity, this Agreement will not be effective with respect to such overlapping services unless and until it is approved by the Hospital
Office of Corporate Sponsored Research and Licensing in consultation with such third party. Consultant shall spend no more than
five (5) business days in performing Services for Company hereunder but may spend any amount of time during weekends, after business
hours, or on holidays in the performance of the Services, as mutually agreed to by Consultant and the Company. As used in each
instance in this Agreement, the term "Services" shall mean the Services as defined and expressly limited in this Section
2. Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement shall be construed to restrict or limit
the duties Consultant is performing or may perform in the course of, or incidental to, Consultant's appointment at Hospital, including
but not limited to research sponsored by a third party commercial entity, nor shall anything in this Agreement be construed to
restrict or limit Consultant's right to serve as an advisor to any hospital, or to any governmental or not-for-profit organization.

 

3)Method of Providing Services.
It is understood that the Company will not control the manner nor prescribe the method by which the Services under this Agreement
are to be performed by Consultant. Consultant shall be available for a teleconference meeting with the management of the Company
at least once per month during the Term. Consultant will perform Services, and may communicate with the Company's management and
other parties, through personal meetings, correspondence, telephone or video conferences, and such other methods, and at such
times, as mutually determined, subject to the reasonable convenience of the parties. Unless requested otherwise by the Company,
Consultant shall communicate with the Company's management through the Company's President. Acting in good faith and consistent
with ordinary business practices with respect to advisory relationships, Consultant shall devote a reasonable amount of time per
month to the provision of the Services described herein.

 

4)Performance. Consultant agrees
to at all times faithfully, industriously, and to the reasonable best of his abilities, experience, and talents, perform all of
the Services that may be required of and from them pursuant to the express and explicit terms hereof.

 

5)Independence of Parties. Nothing
contained in this Agreement shall constitute either party as an employee, partner, co-venturer or agent of the other, it being
intended that each shall act as an independent contractor with respect to the other. Consultant is not authorized to speak on
behalf of the Company or bind it in any manner Consultant's role is exclusively advisory in nature.

 

6)Compensation. 

	a)		Fees. For
                                         and in consideration of the agreement of Consultant to enter into and perform under this
                                         Agreement, the Company shall pay to Consultant $45,000 per annum, payable monthly in
                                         increments of $3,750.

 

    	2

    	 

    

 

	b)		Options.
                                         For and in consideration of the agreement of Consultant to enter into this Agreement
                                         and as a long-term incentive for the Consultant to use their best efforts in pursuit
                                         of the Company's business, the Company shall grant to Consultant an option of similar
                                         tenor to that attached hereto as Exhibit B (the "Option"), provided that the
                                         conditions of Section 8(a) are met. Upon the one-year anniversary of this Agreement,
                                         the Company shall grant to Consultant an option of similar tenor to that attached hereto
                                         as Exhibit B except that the exercise price shall be the closing price of the Company's
                                         common stock as reported on that day.

	c)		Benefits, Other
                                         Consideration. No benefits, vacation pay, or other consideration or remuneration
                                         of any kind shall be owed to Consultant by the Company, unless specifically referenced
                                         herein. Expenses incurred in Consultant's provision of the Services shall be reimbursed
                                         by the Company provided that they are pre-approved in writing by the Company. The Company
                                         shall pay for the cost of regular meetings of the SAB, including meeting room rental
                                         and meals, and any travel expenses beyond $100.

	d)		Reimbursement
                                         of Expenses. The Company shall reimburse all of the reasonable legal fees and expenses
                                         incurred by the Consultant in the negotiation and completion of this Agreement and the
                                         arrangements contemplated hereunder. The Company shall also reimburse all of the reasonable
                                         legal fees and expenses incurred by the Consultant in the review, negotiation, and finalization
                                         of any document or press release which uses Consultant's name. Any such expenses in excess
                                         of $500 shall require the prior, written authorization of the Company.

 

7) Company Representations and Warranties.
The Company hereby represents and warrants, knowing that Consultant is relying thereon, that:

	a)		The Company is duly organized, validly existing and in good standing under the laws
of the state of Delaware. The Company is qualified to do business as a foreign corporation in each state in which its business
requires it to be so qualified.

	b)		Upon receipt of the full exercise price, where applicable, all Shares issued to Consultant
under the Option will be duly and validly issued, fully paid and non-assessable, and will be delivered free and clear of any liens,
claims or encumbrances, except for restrictions imposed by reference to the registration requirements of the Securities Act of
1933.

	c)		The Company represents that the information concerning the Company and its business,
as furnished and to be furnished to Consultant in writing, will be complete and correct in all material respects and will not
contain any untrue statement of material fact or omit to state a material fact necessary in order to make the statements therein
not misleading in light of the circumstances under which such statements are made. The Company will notify Consultant promptly
concerning any statement which is not accurate or which is or has become incomplete or misleading in any material respect. The
Company understands that Consultant is and will be relying on the continuing accuracy of such information in carrying out its
functions under this Agreement.

8) Consultant Representations. Consultant
hereby represents, knowing that the Company is relying thereon, that:

 

	a)		Consultant is an Accredited Investor, as that term is defined in Regulation D in the
Securities Act, 1933, and Consultant has completed the attached Exhibit C, or lieu of this, Consultant agrees that the Option
shall only be issued immediately upon the availability of an appropriate exemption from registration or an effective registration
statement;

	b)		Consultant has not in the past, nor will he in the future engage in any activity contrary
to the securities laws of any jurisdiction including, without limitation, those of the United States of America; and

	c)		Consultant has read and accepted the Viral Genetics Intellectual Property Agreement,
attached hereto as Exhibit D, which is part of this Agreement and the provisions of which shall survive the expiration or earlier
termination of this Agreement in strict accordance with the time periods as described therein.

 

    	3

    	 

    

 

9)Stock Certificates. All Shares
delivered to Consultant pursuant to exercise of the Option shall bear a restrictive legend in the form normally used by the Company
for the issuance of restricted shares, and shall be deemed restricted securities under SEC Rule 144.

 

10)Changes to Common Stock. In
the event that the Company shall undertake a recapitalization, reverse stock split, forward stock split, reclassification, or
other change to its common stock (a "Change in Common Stock Properties"), the quantity of Shares which may be acquired
through exercise of any delivered but unexercised Options or undelivered Options, and the exercise price payable thereto shall
be increased or decreased proportionately, in accordance with the terms of said Change in Common Stock Properties.

 

11)Extension and Renewal. The Term
may be extended or renewed, and this Agreement may be amended, only by the written agreement of the parties.

 

12)Indemnification.

 

	a)		The Company hereby indemnifies and defends the Consultant and each of his executors,
heirs, assigns, and representatives, as applicable, (each, an "Indemnitee") against, and holds each Indemnitee harmless
from, any loss, liability, obligation, deficiency, damage or expense including, without limitation, interest, penalties, reasonable
attorneys' fees and disbursements (collectively, "Damages"), that any Indemnitee may suffer or incur based upon, arising
out of, relating to or in connection with (whether or not in connection with any third party claim):

	i)		any breach of any representation or warranty made by the Company contained in this
Agreement;

	ii)		the failure of the Company to perform or to comply with any covenant or condition
required to be performed or complied with in accordance with this Agreement; and

	iii)		the good faith performance of the Services.

	b)		Indemnification Procedures for Third Party Claims.

	i)		Promptly after notice to an Indemnitee of any claim or the commencement of any action
or proceeding, including any actions or proceedings by a third party (hereafter referred to as "Proceeding" or "Proceedings"),
involving any Damage referred to in this Section, such Indemnitee shall, if a claim for indemnification in respect thereof is
to be made against an Indemnitee pursuant to this Section, give written notice to the Company, setting forth in reasonable detail
the nature thereof and the basis upon which such party seeks indemnification hereunder; provided, however, that the failure of
any Indemnitee to give such notice shall not relieve the Company of its obligations hereunder, except to the extent that the Company
is actually prejudiced by the failure to give such notice.

	ii)		In the case of any Proceeding by a third party against an Indemnitee, the Company
shall, upon notice as provided above, assume the defense thereof, with counsel reasonably satisfactory to the Indemnitee, and,
after notice from the Company to the Indemnitee of its assumption of the defense thereof, the Company shall not be liable to such
Indemnitee for any legal or other expenses subsequently incurred by the Indemnitee in connection with the defense thereof (but
the Indemnitee shall have the right, but not the obligation, to participate at its own cost and expense in such defense by counsel
of its own choice) or for any amounts paid or foregone by the Indemnitee as a result of any settlement or compromise thereof that
is effected by the Indemnitee (without the written consent of the Company).

 

    	4

    	 

    

 

	iii)		Anything in this Section 12 notwithstanding, if both the Company and the Indemnitee
are named as parties or subject to such Proceeding and either party determines with advice of counsel that there may be one or
more legal defenses available to it that are different from or additional to those available to the other party or that a material
conflict of interest between such parties may exist in respect of such Proceeding, then the Company may decline to assume the
defense on behalf of the Indemnitee or the Indemnitee may retain the defense on its own behalf, and, in either such case, after
notice to such effect is duly given hereunder to the other party, the Company shall be relieved of its obligation to assume the
defense on behalf of the Indemnitee, but shall be required to pay any legal or other expenses including, without limitation, reasonable
attorneys' fees and disbursements, incurred by the Indemnitee in such defense.

	iv)		If the Company assumes the defense of any such Proceeding, the Indemntiee shall cooperate
fully with the Company and shall appear and give testimony, produce documents and other tangible evidence, and otherwise assist
the Company in conducting such defense. The Company shall not, without the consent of the Indemnitee, consent to entry of any
judgment or enter into any settlement or compromise which does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such Indemnitee of a release from all liability in respect of such claim or Proceeding. Provided that
proper notice is duly given, if the Company shall fail promptly and diligently to assume the defense thereof, then the Indemnitee
may respond to, contest and defend against such Proceeding and may make in good faith any compromise or settlement with respect
thereto, and recover from the Company the entire cost and expense thereof including, without limitation, reasonable attorneys'
fees and disbursements and all amounts paid or foregone as a result of such Proceeding, or the settlement or compromise thereof.
The indemnification required hereunder shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills or invoices are received or loss, liability, obligation, damage or expense is actually suffered
or incurred.

 

	c)		Each of the Company and Consultant acknowledges and agrees that (i) Consultant is
entering into this Agreement in his individual capacity and not as an employee or agent of Hospital, and (ii) Hospital is not
a party to this Agreement and has no liability or obligation whatsoever hereunder. The provisions of this paragraph shall survive
the expiration or earlier termination of this Agreement.

	d)		The provisions of this section 12 shall survive the expiration or earlier termination
of this Agreement.

 

13) Termination.

	a)		Either party may terminate this Agreement upon not less than 15 days notice in the
event of a

material breach of this Agreement or material non-performance by the other party, which breach is not cured within 10 days after
the giving of written notice to the breaching party specifying the circumstances of such breach.

	b)		The Company may terminate this Agreement without further notice to Consultant in the
event that Consultant:

	i)		is convicted a felony or a violation of any securities laws;

	ii)		declares bankruptcy;

	iii)		has been grossly negligent in the performance of Services at least three times in
any consecutive 30-day period, and Consultant has been notified in writing within 5 days of each such occurrence; or

	iv)		has engaged in material and willful or gross misconduct in the performance of Services
hereunder.

	c)		Either party may terminate this Agreement without cause upon 30 days prior written
notice to the other party.

 

    	5

    	 

    

 

14)Consequences of Termination.
Any termination or expiration of this Agreement, whether or not for cause, shall not affect the obligation of the Company to pay
compensation to Consultant that was earned or accrued prior to the date of termination or expiration. Other than as specifically
provided for herein, no further fees or payments of any kind shall be owed to Consultant upon or following Termination.

 

15)Cooperation. The parties shall
deal with each other in good faith, good faith meaning honesty in fact and the observance of all commercial standards of fair
dealing and usages of trade, which are regularly observed within the industry.

 

16)No Strict Construction. The
language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent,
and no rule of strict construction shall be applied against any party.

 

17)Arbitration. In the event of
dispute or controversy between the parties as to the performance hereof, this Agreement shall be and remain in full force and
effect and all terms hereof shall continue to be complied with by both parties, it shall be submitted to two arbitrators, one
to be appointed by each, and if those arbitrators do not agree, they shall select a third disinterested and competent person to
act with them, and the decision of the three, or a majority of them, shall be final and conclusive. If either party does not appoint
an arbitrator as aforesaid within 90 days after receipt of notice to the other that it desires arbitration, which notice shall
state the name and address of the arbitrator appointed by such other, and does not within such period furnish to such other party
the name and address of the second arbitrator, then the arbitrator first named shall appoint a disinterested and competent arbitrator
for the party thus defaulting, and the two arbitrators so appointed shall select a third to act with them as aforesaid and with
like effect. Cost of arbitration shall be borne by the Company. Judgment upon the reward rendered may be entered in any court
having jurisdiction thereof.

 

18)Governing Law and Disputes. This
Agreement shall be governed by the laws of the Commonwealth of Massachusetts, without regard to choice of law provisions.

 

19)Waiver. Any party hereto may
waive compliance by the other with any of the terms, provisions and conditions set forth herein; provided, however, that any such
waiver shall be in writing specifically setting forth those provisions waived thereby. No such waiver shall be deemed to constitute
or imply waiver of any other term, provision or condition of this Agreement.

 

20)Severability. If and to the
extent that any court of competent jurisdiction holds any provision or any part thereof of this Agreement to be invalid or unenforceable,
such holding shall in no way affect the validity of the remainder of this Agreement.

 

21)Counterpart and Headings. This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall
constitute one and the same instrument. All headings in this Agreement are inserted for convenience of reference and shall not
affect its meaning or interpretation.

 

22)Entire Agreement. This Agreement is
and shall be considered to be the only agreement or understanding between the parties hereto with respect to the engagement of
Consultant by the Company. All negotiations, commitments, and understandings acceptable to both parties have been incorporated
herein. No letter, telegram, or communication passing between the parties hereto shall be deemed a part of this Agreement; nor
shall it have the effect of modifying or adding to this Agreement unless it is distinctly stated in such letter, telegram, or
communication that it is to constitute a part of this Agreement and is to be attached as a rider to this Agreement and is signed
by the parties to this Agreement.

 

    	6

    	 

    

 

23)Modification of Contract. This
Agreement cannot be modified by tender, acceptance or endorsement of any instrument of payment, including check. Any words contained
in an instrument of payment modifying this contract, including a waiver or release of any claims, or a statement referring to
paying in full is void. This Agreement can only be modified in a separate writing, other than an instrument of payment, signed
by the parties.

 

24)Enforcement. Consultant acknowledges
that any remedy at law for breach of Sections 10, 11 or Exhibit D would be inadequate, acknowledges that the Company would be
irreparably damaged by an actual or threatened breach thereof, and agrees that the Company shall be entitled to an injunction
restraining Consultant from any actual or threatened breach of Section 10, 11 or Exhibit D as well as any further appropriate
equitable relief without any bond or other security being required. The Company may pursue enforcement of Sections 10, 11 or Exhibit
D by commencing an action at law or in equity without first pursuing arbitration pursuant to Section 17 of this Agreement. In
addition to the foregoing, each of the parties hereto shall be entitled to any remedies available in equity or by statute with
respect to the breach of the terms of this Agreement by the other party.

 

25)Assignment. The provisions of
this Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective heirs, legal representatives,
successors and assigns. This Agreement may not be assigned without the consent of the parties; provided, however, that
nothing contained herein shall prevent Consultant from assigning or transferring any of the Shares or Options to any person or
entity in accordance with applicable securities laws and regulations.

 

26)Notices. All notices under this
Agreement shall be in writing and shall be sent by certified or registered first class mail, return receipt requested, or shall
be personally delivered, or sent by an overnight delivery service such as Federal Express, or shall be transmitted by telefax
(provided such telefax message is confirmed by telephonic acknowledgment of receipt or by sending via other authorized means a
confirmation copy of such notice) addressed to the parties at their respective last known business addresses.

 

27)Use of Name. Neither the name
of the Consultant nor that of Hospital, nor Partners HealthCare System, Inc., nor any variation thereon nor adaptation thereof
may be used in any advertising, promotional or sales literature, or other publicity without the prior written approval of the
party whose name is to be used. The provisions of this paragraph shall survive the expiration or earlier termination of this Agreement.

 

Agreed to this 1st day of July, 2006.

 

	VIRAL GENETICS, INC.	ERIC S. ROSENBERG, MD
	 	 
	By: /s/ Haig Keledjian	/s/ Eric S. Rosenberg MD
	        President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]